A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804
Stopped early · Phase 1
Conditions studied: Non-Small Cell Lung Cancer (NSCLC)
In brief
This study will enroll patients who are planned to undergo surgical removal of their tumor. The goal of the study is to evaluate the changes that occur in the tumor after brief (about 8 days) exposure to the study drug.
Key facts
- Study ID
- NCT00971191
- Run by
- Pfizer
- People needed
- 22
- Starts
- 2010-02-01
- Expected to finish
- 2012-05-01
- Last updated by the study team
- 2012-06-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Radiographs consistent with lung cancer for which resection is indicated upon histologic confirmation of non-small cell lung cancer.
- Patient willing to take PF-00299804 for 5 to 11 days and provide blood and tissue specimens as required in the study.
You may not qualify if…
- Prior or concurrent systemic anticancer therapy for cancer (immunotherapy, hormonotherapy, biological therapy, or chemotherapy) less than one year from time of consent.
- Prior or concurrent radiation therapy to tumor at site of planned resection.
- Congestive heart failure (LVEF < 50%), uncontrolled hypertension, significant ventricular arrythmia.
- Drugs that are highly dependent on CYP2D6 for metabolism, or are generally accepted to have a risk of causing Torsades de Pointes.
- Prior or concurrent radiation therapy to tumor at site of planned resection.
Where it is running
- Pfizer Investigational Site — Birmingham, Alabama, United States
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.